Satellos Bioscience Inc.
TSX:MSCL.TOBiotechnology
+$0.01 today
- Market cap
- $182.89M
- Beta
- 1.17
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.32
Volume 0.01M
Average 0.02M
MSCL.TO Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
Satellos Bioscience Inc.TSX: MSCL.TO
Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026
Other non-cash items turns positive
Q1 FY2026 other non-cash items was $150.36K, compared with -$3K a year earlier. Trailing-twelve-month other non-cash items was $662.57K.
Context
- Other non-cash items increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly other non-cash items holds near $150.36K or moves back toward the trailing-twelve-month quarterly average of $165.64K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Non-Cash Items history
Mixed currencies · from the cash flow
- Latest · FY2025
- (435.77K) USD
- Year-over-year change
- —
| Period | Period end | Other Non-Cash Items | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (435.77K) | — |
| FY2024 | 2024-12-31 | 2.02M | +287.9% |
| FY2023 | 2023-12-31 | (1.07M) | -136.9% |
| FY2022 | 2022-12-31 | 2.91M | -70.4% |
| FY2021 | 2021-12-31 | 9.82M | — |
Other Non-Cash Items vs competitors
How MSCL.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-cash items is compared through growth and share of revenue rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | CA$2.18M CAD | +1679.7% | — | — | |
| LTM Mar 2026 | CA$1.09M CAD | +133.0% | -75.6% | — | |
MSCL.TOSatellos Bioscience Inc. | LTM Mar 2026 | $662.57K USD | — | — | — |
| LTM Apr 2026 | CA$107K CAD | +164.1% | -60.4% | — | |
| Peer median (excluding MSCL.TO) | — | +164.1% | -68.0% | — | |
Competitors are the stored peer set for MSCL.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · CAD | FY2024 Dec 2024 · CAD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Net Income | (15.51M) | (11.32M) | (15.89M) | (28.1M) | (25.31M) |
| Depreciation & Amortization | 165.69K | 337K | 7K | 20K | 4K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 971.53K | 1.44M | 2.17M | 2.11M | 3.24M |
| Change in Working Capital | (485.64K) | 991K | 369K | (1.03M) | (1.5M) |
| Accounts Receivables | (67.4K) | 267.55K | (323K) | (43K) | 66.14K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (390.47K) | 726.11K | 0 | 0 | 0 |
| Other Working Capital | (27.77K) | (1.93K) | 692K | (982K) | (1.57M) |
| Other Non-Cash Items | 9.82M | 2.91M | (1.07M) | 2.02M | (435.77K) |
| Operating Cash Flow | (5.03M) | (5.78M) | (14.5M) | (24.98M) | (24.01M) |
| Capital Expenditures | (7.25K) | (3K) | (18K) | (6K) | (6.1K) |
| Acquisitions (Net) | 1.75M | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (17.52M) | (37.34M) | (23.78M) |
| Sales of Investments | 0 | 0 | 0 | 43.68M | 14.2M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 1.74M | (3K) | (17.54M) | 6.34M | (9.58M) |
| Debt Repayment | 186.57K | 0 | (284K) | 0 | 0 |
| Common Stock Issued | 7.08M | 2.78M | 32.46M | 42.8M | 2.28M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 185.46K | 0 | 18.85M | 10.68M | 0 |
| Financing Cash Flow | 7.45M | 2.78M | 51.03M | 53.49M | 2.28M |
| Effect of Forex Changes | (1.44K) | (76K) | 1.15M | 744K | (890.45K) |
| Net Change in Cash | 4.15M | (2.95M) | 20.14M | 35.59M | (32.2M) |
| Free Cash Flow | (5.04M) | (5.79M) | (14.52M) | (24.98M) | (24.02M) |
Satellos Bioscience Inc.
TSX:MSCL.TO
Intrinsic Alpha fair value
Locked
Current Price
$8.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.